Johnson & Johnson (ETR:JNJ)
Germany
· Delayed Price · Currency is EUR | Market Cap | 364.18B |
| Revenue (ttm) | 85.17B |
| Net Income (ttm) | 13.49B |
| Shares Out | n/a |
| EPS (ttm) | 5.55 |
| PE Ratio | 27.00 |
| Forward PE | n/a |
| Dividend | 4.62 (3.05%) |
| Ex-Dividend Date | Feb 18, 2025 |
| Volume | 2,202 |
| Average Volume | 5,664 |
| Open | 151.38 |
| Previous Close | 151.40 |
| Day's Range | 150.90 - 151.90 |
| 52-Week Range | 132.78 - 161.30 |
| Beta | 0.46 |
| RSI | 51.18 |
| Earnings Date | Apr 15, 2025 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial numbers in USD Financial StatementsNews
Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.
Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-...
Strategically Building A $100,000 Dividend Portfolio For Attractive Income And Strong Risk-Adjusted Returns
The Dividend Income Accelerator Portfolio focuses on financially healthy companies with strong balance sheets, aiming to generate sustainable dividend income and reduce portfolio volatility. Recent ad...
The Big 3: JNJ, GE, LULU
Healthcare headwinds have @Theotrade's Don Kaufman leaning bearish on Johnson & Johnson (JNJ) while staying bullish in GE Aerospace (GE) despite hitting 18-year highs today. He offers options trades i...
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer
Median overall survival not yet reached with projected improvement of more than one year versus osimertinib RARITAN, N.J. , March 26, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced ...
Tech struggles while oil and financials rise: A comprehensive market snapshot
The U.S. stock market today displayed a stark contrast in sector performances, with technology facing significant challenges while oil and financials seemed to gain investor favor. The market dynamics...
New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)
Oral presentation features new data from the 24-week pivotal Vivacity-MG3 study which show sustained disease control through treatment with nipocalimab on the clinician-assessed QMGa score in antibody...
Tech sector dominates: Meta and Apple lead today's market surge
The stock market today is showcasing an impressive performance in the technology sector, with Meta and Apple leading the charge against a backdrop of varied sector responses. Investors are attentively...
BofA reveals stocks with a history of steady returns amid market volatility
Trump tariffs have already hurt US stocks significantly in recent weeks but the Fed's latest warning of stickier inflation and an economic slowdown ahead signals the worst may not be over just yet.
2 Dividend Picks Yielding Up To 5.67% For A Balanced Income & Growth Portfolio
I have added Canadian Natural Resources and NextEra Energy to The Dividend Income Accelerator Portfolio, each representing 2.19% of our overall portfolio. These strategic acquisitions help us to furth...
2025 Dividend Kings: Strong Run Continues
The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings i...
J&J boosts investments in U.S. to more than US$55 billion amid looming tariff threats
Johnson & Johnson plans to spend more than US$55 billion to build plants in the U.S. over the next four years, after the threat of drug import duties by tariffs.
Johnson & Johnson to Invest Over $55 Billion in U.S. in Next Four Years
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the first and only IL-23 inhibitor offering subcutaneous (SC) and intravenous (IV...
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's (NYSE JNJ) Tremfya (guselkumab), the first and only IL-23 inhibitor offering subcutaneous (SC) and intravenous (IV...
J&J boosts investments in US to more than $55 billion amid looming tariff threats
Johnson & Johnson plans to spend over $55 billion to build four plants in the U.S., it said on Friday. The new plants will be built over the next four years.
J&J wins FDA label expansion for fourth U.S. indication
Johnson & Johnson (JNJ) win FDA approval for its bowel disease therapy Tremfya for Crohn's disease, its fourth U.S.-approved indication. Read more here.
Johnson & Johnson to boost U.S. investments to over $55B
J&J plans to invest more than $55 billion in US over next four years
Johnson & Johnson said on Friday it plans to invest more than $55 billion over the next four years to build manufacturing facilities and research infrastructure in the United States.
Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Today, Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare's leading, most comprehensive innovation powerhouse, announced manufacturing, research and develo...
Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years
Today, Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, announced manufacturing, research and development, and technology investments of m...
Historic Dividend Outperformance
For year to date performance, the biggest losers are now mostly growth factors, whereas low volatility and dividend focused ETFs are actually still in the green so far in 2025. One of the most well-kn...
U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease
TREMFYA ® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen Supported by data from the GALAXI study, TREMFYA ®...
U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease
TREMFYA® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen Supported by data from the GALAXI study, TREMFYA® i...
DARZALEX Continues to Redefine Multiple Myeloma Treatment with Robust Market Performance | DelveInsight
DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory patient...
Johnson & Johnson's Golden Cross: Technical Momentum Meets Groundbreaking Lung Cancer Breakthrough
Johnson & Johnson (NYSE: JNJ) just hit a Golden Cross , a classic bullish technical pattern that signals potential long-term upside. The stock's 50-day simple moving average crossed above its 200-day...